Adzynma Wins FDA Approval as First Treatment for Ultra-Rare Blood Clotting Disorder cTTP
XTalks
NOVEMBER 10, 2023
The US Food and Drug Administration (FDA) has approved Takeda Pharmaceuticals’ Adzynma, the first recombinant protein product for prophylactic (preventive) or on‑demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), an ultra-rare blood clotting disorder.
Let's personalize your content